首页 > 市场调查报告书 > 医疗设备

体外诊断 POC诊断

POC (照护现场) 检验的全球市场 (2022-2030年):市场规模 (各产品、技术、处方、用途、终端用户)、地区的展望、用途的潜在性、市场占有率、预测

市场调查报告书

商品编码

1100652

POC (照护现场) 检验的全球市场 (2022-2030年):市场规模 (各产品、技术、处方、用途、终端用户)、地区的展望、用途的潜在性、市场占有率、预测

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 - 2030

出版日期: 2022年07月06日 | 出版商:

Global Market Insights Inc. | 英文 430 Pages | 商品交期: 2-3个工作天内

价格

简介目录

POC (照护现场) 检验的市场，由于急性疾病患者增加，预计2030年大幅成长。近几年，由于新型冠状病毒感染疾病 (COVID-19) 的暴露风险在医院的检验减少，POC检验的产品需求也提高。还有POC检验的重要优点的快速检验，在COVID-19大流行时带来了正面的影响。

各产品中，血液检验产品的部门2021年显示约38亿9,170万美元，预计2030年也取得大规模的利益。各技术中，分子诊断药的部门在预测期间内预计记录约8.0％的年复合成长率。

本报告提供全球POC (照护现场) 检验的市场调查，市场定义和概要，市场成长的各种影响因素分析，市场规模的变化、预测，各种区分、各地区/主要国家的明细，竞争环境，主要企业简介等彙整资讯。

主要趋势
血糖监测系统
- 带
- 计器
- 采血针
心臟代谢检验产品
- 心臟标记检验产品
- 血气/电解质检验产品
- HBA1C检验产品
传染病检查产品
- 流感检验产品
- HIV检验产品
- C型肝炎检验产品
- 性感染疾病(STD)检验产品
- 医疗相关感染(HAI)检验产品
- 呼吸系统传染病检查产品
- 热带病检验产品
- 其他的传染病检查产品
血液凝固检验产品
- PT/INR检验产品
- 活性化凝固时间(ACT/APTT)检验产品
妊娠及出生力检验产品
- 妊娠检验产品
- 出生力检验产品
肿瘤/癌症标记检验产品
胆固醇检验产品
血液检验产品
药物滥用(DoA)检验产品
大便潜血试验产品
尿液检查产品
其他

第5章 POC (照护现场) 检验市场:各技术

主要趋势
侧向流动分析
沾棒
微流体
分子诊断
免疫学的检验
凝集化验
流通
固相检验
生物感应器

第6章 POC (照护现场) 检验市场:各处方

主要趋势
OTC检验
处方检验

第7章 POC (照护现场) 检验市场:各用途

主要趋势
心臟代谢检验
传染病检查
肾臟检验
药物滥用(DoA)检验
血糖值检验
妊娠检验
癌症生物标记检验
其他

第8章 POC (照护现场) 检验市场:各终端用户

主要趋势
医院
诊断中心
研究实验室
居家照护
其他

第9章 POC (照护现场) 检验市场:各地区

主要趋势
北美
欧洲
亚太地区
南美
中东、非洲

第10章企业简介

竞争仪表板
Abaxis
Abbott
Accubiotech Co, Ltd.
ACON Laboratories, Inc
Becton, Dickinson and Company
bioLytical Laboratories Inc
BioMrieux SA
Bio-Rad Laboratories, Inc
HemoCue AB(Danaher Corporation)
Dexcom, Inc
Dragerwerk Ag & Co
LifeScan IP Holdings, LLC
Medtronic plc
Meridian Bioscience, Inc
Nova Biomedical
OraSure Technologies, Inc
F. Hoffmann-La Roche
Siemens Healthineers AG
Sysmex Corporation
Trinity Biotech

简介目录

Product Code: 3086

The point of care testing market is expected to witness massive growth through 2030 owing to increasing number of patients with acute illnesses.

Recently, testing in hospitals saw a decline due to the risk of exposure to the novel coronavirus in these settings, which fueled product demand as point of care testing offers flexibility with regards to location. Additionally, rapid testing, a pivotal advantage of point of care assays, has also positively influenced market uptake during the COVID-19 pandemic.

Notably, surging research emphasis by industry players has been beneficial for the product landscape, which has enhanced overall market dynamics. For instance, in June 2022, LumiraDx, a UK-based diagnostics company reported that it had gained CE Mark for its product, the Amira Analyzer. This portable instrument is used for rapid COVID-19 testing.

The point of care testing market has been bifurcated on the basis of technology, application, product, prescription, end-use, and region.

On the basis of product, the market has been bifurcated into cardiometabolic testing products, coagulation testing products, tumor/cancer marker testing products, Drug-of-Abuse (DoA) testing products, cholesterol testing products, glucose monitoring, infectious disease testing products, pregnancy and fertility testing products, urinalysis testing products, hematology testing products, fecal occult testing products, and other products. Among these, the hematology testing products segment was valued at approximately $3,891.7 million in 2021 and is speculated to amass notable gains over 2022-2030.

In terms of technology, the point of care testing market has been segmented into dipsticks, molecular diagnostics, agglutination assays, solid phase, biosensors, flow-through, immunoassays, microfluidics, and lateral flow assays. The molecular diagnostics segment is expected to register a CAGR of around 8.0% over the analysis timeframe.

In context of prescription, the market has been divided into prescription-based testing and OTC testing. The prescription-based testing segment contributed to a market share of roughly 46.1% in 2021 and is estimated to exhibit solid growth in the upcoming time period.

Based on application, the point of care testing market has been divided into infectious disease testing, Drug-of-Abuse (DoA) testing, pregnancy testing, cardio metabolic testing, nephrology testing, blood glucose testing, cancer biomarker testing, and other applications. The infectious disease testing segment is set to witness steady growth, expanding at around 8.1% CAGR through the review period.

On the basis of end-use, the market has been divided into diagnostic centers, home-care settings, hospitals, research laboratories, and others. The research laboratories segment reached more than $4,111.8 million in revenue in 2021.

On the regional front, the point of care testing market in Latin America accounted for nearly 5.8% of the overall industry revenue in 2021. On the other hand, the Middle East & Africa point of care testing industry is set to experience robust growth at a CAGR of about 8.6% over the forecast period.

Chapter 1 Methodology

1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data Sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Point of care testing industry 360 degree synopsis, 2017 - 2030
- 2.1.1 Business trends
- 2.1.2 Product trends
- 2.1.3 Technology trends
- 2.1.4 Prescription trends
- 2.1.5 Application trends
- 2.1.6 End-use trends
- 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Upward trend in disease prevalence among developing countries
  - 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
  - 3.3.1.3 Technological advancements
  - 3.3.1.4 Increasing R&D investment
  - 3.3.1.5 Growing geriatric population base globally
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Increasing R&D investment
  - 3.3.2.2 High cost of product development
3.4 Growth potential analysis
- 3.4.1 By product
- 3.4.2 By technology
- 3.4.3 By prescription
- 3.4.4 By application
- 3.4.5 By end-use
3.5 COVID-19 impact analysis
3.6 Pricing analysis, by cardiac markers, 2021
3.7 Regulatory landscape
3.8 Technology landscape
3.9 Company share analysis, 2021 (by region)
- 3.9.1 Global market share analysis, 2021
- 3.9.2 North America
- 3.9.3 Europe
- 3.9.4 Asia Pacific
- 3.9.5 Latin America
- 3.9.6 MEA
3.10 Porter's analysis
3.11 Competitive landscape, 2021
- 3.11.1 Company matrix analysis, 2021
3.12 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

4.1 Key segment trends
4.2 Glucose monitoring
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.2 Strips
  - 4.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.3 Meters
  - 4.2.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.4 Lancets
  - 4.2.4.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Cardiometabolic testing products
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.3.2 Cardiac marker testing products
  - 4.3.2.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.2 High sensitivity troponin I (hsTnI)
    - 4.3.2.2.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.3 Brain natriuretic peptide (BNP)
    - 4.3.2.3.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.4 D-dimer
    - 4.3.2.4.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.5 Creatine kinase-MB (CK-MB)
    - 4.3.2.5.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.6 Myoglobin
    - 4.3.2.6.1 Market size, by region, 2017-2030 (USD Million)
  - 4.3.2.7 Others
    - 4.3.2.7.1 Market size, by region, 2017-2030 (USD Million)
- 4.3.3 Blood Gas/Electrolytes testing products
  - 4.3.3.1 Market size, by region, 2017-2030 (USD Million)
- 4.3.4 HBA1C testing products
  - 4.3.4.1 Market size, by region, 2017-2030 (USD Million)
4.4 Infectious disease testing products
- 4.4.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.2 Influenza testing products
  - 4.4.2.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.3 HIV testing products
  - 4.4.3.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.4 Hepatitis C testing products
  - 4.4.4.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.5 Sexually transmitted disease (STD) testing products
  - 4.4.5.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.6 Healthcare-associated Infection (HAI) testing products
  - 4.4.6.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.7 Respiratory infection testing products
  - 4.4.7.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.8 Tropical disease testing products
  - 4.4.8.1 Market size, by region, 2017-2030 (USD Million)
- 4.4.9 Other infectious diseases testing products
  - 4.4.9.1 Market size, by region, 2017-2030 (USD Million)
4.5 Coagulation testing products
- 4.5.1 Market size, by region, 2017-2030 (USD Million)
- 4.5.2 PT/INR testing products
  - 4.5.2.1 Market size, by region, 2017-2030 (USD Million)
- 4.5.3 Activated clotting time (ACT/APTT) testing products
  - 4.5.3.1 Market size, by region, 2017-2030 (USD Million)
4.6 Pregnancy & fertility testing products
- 4.6.1 Market size, by region, 2017-2030 (USD Million)
- 4.6.2 Pregnancy testing products
  - 4.6.2.1 Market size, by region, 2017-2030 (USD Million)
- 4.6.3 Fertility testing products
  - 4.6.3.1 Market size, by region, 2017-2030 (USD Million)
4.7 Tumor/Cancer marker testing products
- 4.7.1 Market size, by region, 2017-2030 (USD Million)
4.8 Cholesterol testing products
- 4.8.1 Market size, by region, 2017-2030 (USD Million)
4.9 Hematology testing products
- 4.9.1 Market size, by region, 2017-2030 (USD Million)
4.10 Drug-of-Abuse (DoA) testing products
- 4.10.1 Market size, by region, 2017-2030 (USD Million)
4.11 Fecal occult testing products
- 4.11.1 Market size, by region, 2017-2030 (USD Million)
4.12 Urinalysis testing products
- 4.12.1 Market size, by region, 2017-2030 (USD Million)
4.13 Other products
- 4.13.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

5.1 Key segment trends
5.2 Lateral flow assays
- 5.2.1 Market size, by region, 2017 - 2030 (USD Million)
5.3 Dipsticks
- 5.3.1 Market size, by region, 2017 - 2030 (USD Million)
5.4 Microfluidics
- 5.4.1 Market size, by region, 2017 - 2030 (USD Million)
5.5 Molecular diagnostics
- 5.5.1 Market size, by region, 2017 - 2030 (USD Million)
5.6 Immunoassays
- 5.6.1 Market size, by region, 2017 - 2030 (USD Million)
5.7 Agglutination assays
- 5.7.1 Market size, by region, 2017 - 2030 (USD Million)
5.8 Flow-through
- 5.8.1 Market size, by region, 2017 - 2030 (USD Million)
5.9 Solid phase
- 5.9.1 Market size, by region, 2017 - 2030 (USD Million)
5.10 Biosensors
- 5.10.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

6.1 Key segment trends
6.2 OTC testing
- 6.2.1 Market size, by region, 2017 - 2030 (USD Million)
6.3 Prescription-based testing
- 6.3.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

7.1 Key segment trends
7.2 Cardio metabolic testing
- 7.2.1 Market size, by region, 2017 - 2030 (USD Million)
7.3 Infectious disease testing
- 7.3.1 Market size, by region, 2017 - 2030 (USD Million)
7.4 Nephrology testing
- 7.4.1 Market size, by region, 2017 - 2030 (USD Million)
7.5 Drug-of-Abuse (DoA) testing
- 7.5.1 Market size, by region, 2017 - 2030 (USD Million)
7.6 Blood glucose testing
- 7.6.1 Market size, by region, 2017 - 2030 (USD Million)
7.7 Pregnancy testing
- 7.7.1 Market size, by region, 2017 - 2030 (USD Million)
7.8 Cancer biomarker testing
- 7.8.1 Market size, by region, 2017 - 2030 (USD Million)
7.9 Other applications
- 7.9.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

8.1 Key segment trends
8.2 Hospitals
- 8.2.1 Market size, by region, 2017 - 2030 (USD Million)
8.3 Diagnostic centers
- 8.3.1 Market size, by region, 2017 - 2030 (USD Million)
8.4 Research laboratories
- 8.4.1 Market size, by region, 2017 - 2030 (USD Million)
8.5 Home-care settings
- 8.5.1 Market size, by region, 2017 - 2030 (USD Million)
8.6 other
- 8.6.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

9.1 Key regional trends
9.2 North America
- 9.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.2.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.2.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.2.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.2.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.2.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.2.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.2.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.2.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.2.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.2.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.2.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.2.7 U.S.
  - 9.2.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.2.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.2.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.2.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.2.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.2.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.2.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.2.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.2.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.2.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.2.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.2.8 Canada
  - 9.2.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.2.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.2.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.2.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.2.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.2.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.2.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.2.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.2.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.2.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.2.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.3 Europe
- 9.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.3.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.3.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.3.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.3.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.3.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.3.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.3.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.3.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.3.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.3.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.7 Germany
  - 9.3.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.8 UK
  - 9.3.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.9 France
  - 9.3.9.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.9.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.9.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.9.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.9.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.9.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.9.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.9.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.9.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.9.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.9.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.10 Spain
  - 9.3.10.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.10.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.10.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.10.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.10.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.10.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.10.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.10.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.10.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.10.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.10.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.3.11 Italy
  - 9.3.11.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.3.11.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.3.11.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.3.11.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.3.11.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.3.11.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.3.11.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.3.11.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.3.11.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.3.11.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.3.11.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.4 Asia Pacific
- 9.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.4.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.4.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.4.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.4.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.4.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.4.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.4.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.4.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.4.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.4.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.7 China
  - 9.4.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.8 India
  - 9.4.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.9 Japan
  - 9.4.9.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.9.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.9.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.9.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.9.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.9.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.9.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.9.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.9.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.9.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.9.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.4.10 Australia
  - 9.4.10.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.4.10.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.4.10.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.4.10.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.4.10.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.4.10.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.4.10.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.4.10.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.4.10.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.4.10.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.4.10.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.5 Latin America
- 9.5.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.5.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.5.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.5.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.5.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.5.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.5.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.5.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.5.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.5.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.5.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.5.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.5.7 Brazil
  - 9.5.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.5.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.5.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.5.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.5.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.5.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.5.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.5.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.5.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.5.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.5.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.5.8 Mexico
  - 9.5.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.5.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.5.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.5.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.5.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.5.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.5.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.5.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.5.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.5.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.5.8.5 Market size, by end-use, 2017 - 2030 (USD Million)
9.6 MEA
- 9.6.1 Market size, by country, 2017 - 2030 (USD Million)
- 9.6.2 Market size, by product, 2017 - 2030 (USD Million)
  - 9.6.2.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
  - 9.6.2.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.6.2.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
  - 9.6.2.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
  - 9.6.2.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
  - 9.6.2.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
- 9.6.3 Market size, by technology, 2017 - 2030 (USD Million)
- 9.6.4 Market size, by prescription, 2017 - 2030 (USD Million)
- 9.6.5 Market size, by application, 2017 - 2030 (USD Million)
- 9.6.6 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.6.7 South Africa
  - 9.6.7.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.6.7.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.6.7.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.6.7.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.6.7.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.6.7.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.6.7.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.6.7.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.6.7.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.6.7.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.6.7.5 Market size, by end-use, 2017 - 2030 (USD Million)
- 9.6.8 Saudi Arabia
  - 9.6.8.1 Market size, by product, 2017 - 2030 (USD Million)
    - 9.6.8.1.1 Market size, by glucose monitoring, 2017-2030 (USD Million)
    - 9.6.8.1.2 Market size, by cardiometabolic testing products, 2017-2030 (USD Million)
    - 9.6.8.1.2.1 Market size, by cardiac marker testing product, 2017-2030 (USD Million)
    - 9.6.8.1.3 Market size, by infectious disease testing products, 2017-2030 (USD Million)
    - 9.6.8.1.4 Market size, by coagulation testing products, 2017-2030 (USD Million)
    - 9.6.8.1.5 Market size, by pregnancy & fertility testing products, 2017-2030 (USD Million)
  - 9.6.8.2 Market size, by technology, 2017 - 2030 (USD Million)
  - 9.6.8.3 Market size, by prescription, 2017 - 2030 (USD Million)
  - 9.6.8.4 Market size, by application, 2017 - 2030 (USD Million)
  - 9.6.8.5 Market size, by end-use, 2017 - 2030 (USD Million)

Chapter 10 Company Profiles

10.1 Competitive dashboard
10.2 Abaxis
- 10.2.1 Business overview
- 10.2.2 Financial data
- 10.2.3 Product landscape
- 10.2.4 Strategic outlook
- 10.2.5 SWOT analysis
10.3 Abbott
- 10.3.1 Business overview
- 10.3.2 Financial data
- 10.3.3 Product landscape
- 10.3.4 Strategic outlook
- 10.3.5 SWOT analysis
10.4 Accubiotech Co, Ltd.
- 10.4.1 Business overview
- 10.4.2 Financial data
- 10.4.3 Product landscape
- 10.4.4 Strategic outlook
- 10.4.5 SWOT analysis
10.5 ACON Laboratories, Inc
- 10.5.1 Business overview
- 10.5.2 Financial data
- 10.5.3 Product landscape
- 10.5.4 Strategic outlook
- 10.5.5 SWOT analysis
10.6 Becton, Dickinson and Company
- 10.6.1 Business overview
- 10.6.2 Financial data
- 10.6.3 Product landscape
- 10.6.4 Strategic outlook
- 10.6.5 SWOT analysis
10.7 bioLytical Laboratories Inc
- 10.7.1 Business overview
- 10.7.2 Financial data
- 10.7.3 Product landscape
- 10.7.4 Strategic outlook
- 10.7.5 SWOT analysis
10.8 BioMrieux SA
- 10.8.1 Business overview
- 10.8.2 Financial data
- 10.8.3 Product landscape
- 10.8.4 Strategic outlook
10.9 Bio-Rad Laboratories, Inc
- 10.9.1 Business overview
- 10.9.2 Financial data
- 10.9.3 Product landscape
- 10.9.4 Strategic outlook
- 10.9.5 SWOT analysis
10.10 HemoCue AB (Danaher Corporation)
- 10.10.1 Business overview
- 10.10.2 Financial data
- 10.10.3 Product landscape
- 10.10.4 Strategic outlook
- 10.10.5 SWOT analysis
10.11 Dexcom, Inc
- 10.11.1 Business overview
- 10.11.2 Financial data
- 10.11.3 Product landscape
- 10.11.4 Strategic outlook
- 10.11.5 SWOT analysis
10.12 Dragerwerk Ag & Co
- 10.12.1 Business overview
- 10.12.2 Financial data
- 10.12.3 Product landscape
- 10.12.4 Strategic outlook
- 10.12.5 SWOT analysis
10.13 LifeScan IP Holdings, LLC
- 10.13.1 Business overview
- 10.13.2 Financial data
- 10.13.3 Product landscape
- 10.13.4 Strategic outlook
- 10.13.5 SWOT analysis
10.14 Medtronic plc
- 10.14.1 Business overview
- 10.14.2 Financial data
- 10.14.3 Product landscape
- 10.14.4 Strategic outlook
- 10.14.5 SWOT analysis
10.15 Meridian Bioscience, Inc
- 10.15.1 Business overview
- 10.15.2 Financial data
- 10.15.3 Product landscape
- 10.15.4 Strategic outlook
- 10.15.5 SWOT analysis
10.16 Nova Biomedical
- 10.16.1 Business overview
- 10.16.2 Financial data
- 10.16.3 Product landscape
- 10.16.4 Strategic outlook
- 10.16.5 SWOT analysis
10.17 OraSure Technologies, Inc
- 10.17.1 Business overview
- 10.17.2 Financial data
- 10.17.3 Product landscape
- 10.17.4 Strategic outlook
- 10.17.5 SWOT analysis
10.18 F. Hoffmann-La Roche
- 10.18.1 Business overview
- 10.18.2 Financial data
- 10.18.3 Product landscape
- 10.18.4 Strategic outlook
- 10.18.5 SWOT analysis
10.19 Siemens Healthineers AG
- 10.19.1 Business overview
- 10.19.2 Financial data
- 10.19.3 Product landscape
- 10.19.4 Strategic outlook
- 10.19.5 SWOT analysis
10.20 Sysmex Corporation
- 10.20.1 Business overview
- 10.20.2 Financial data
- 10.20.3 Product landscape
- 10.20.4 Strategic outlook
- 10.20.5 SWOT analysis
10.21 Trinity Biotech
- 10.21.1 Business overview
- 10.21.2 Financial data
- 10.21.3 Product landscape
- 10.21.4 Strategic outlook
- 10.21.5 SWOT analysis